LSAT 148 – Section 3 – Question 17

LSAT 148 - Section 3 - Question 17

December 2016

You need a full course to see this video. Enroll now and get started in less than a minute.

Request new explanation

Target time: 1:13

This is question data from the 7Sage LSAT Scorer. You can score your LSATs, track your results, and analyze your performance with pretty charts and vital statistics - all with a Free Account ← sign up in less than 10 seconds

Question
QuickView		 Type Tags Answer
Choices		 Curve Question
Difficulty		 Psg/Game/S
Difficulty		 Explanation
PT148 S3 Q17
+LR
+Exp
Most strongly supported +MSS
Conditional Reasoning +CondR
A
8%
154
B
83%
164
C
4%
156
D
2%
154
E
2%
154
141
148
156
 +Medium 149.233 +SubsectionMedium

The government health service has said that it definitely will not pay for patients to take the influenza medicine Antinfia until the drug’s manufacturer, PharmCo, provides detailed information about Antinfia’s cost-effectiveness. PharmCo has responded that obtaining such information would require massive clinical trials. These trials cannot be performed until the drug is in widespread circulation, something that will happen only if the government health service pays for Antinfia.

Summary
The government will not pay for patients to take Antinfia until the manufacturer provides information about the drug’s cost-effectiveness. This information can only be obtained by performing massive clinical trials. The trials cannot be performed until the drug is in widespread circulation, which will happen only if the government pays for Antinfia.

Strongly Supported Conclusions
Government pays → provide detailed info → massive clinical trails → widespread circulation → government pays
This chain is circular, and the stimulus says the government is not paying. You can run the contrapositive back and draw any valid inference along the chain. (no widespread circulation, no clinical trials, no detailed info)

A
The government health service never pays for any medicine unless that medicine has been shown to be cost-effective.
This is too broad to support. The stimulus is purely focused on Antinfia, not “any medicine”
B
Antinfia will never be in widespread circulation.
The stimulus says that the drug will be in wide circulation only if the government pays. The government is refusing to pay. Thus, it will never be in wide circulation.
C
If the government health service does not pay for Antinfia, then many patients will pay for Antinfia themselves.
The stimulus does not give any information about whether patients will pay out of pocket or not. You need to make some assumptions to make this work
D
The government health service should pay for patients to take Antinfia.
The stimulus does not say whether the government should/should not pay for Antinfia. It only explains what barriers the drug is facing to becoming widely available.
E
Antinfia is not cost-effective.
The stimulus does not say whether Antinfia is/is not cost-effective. The stimulus only notes that the drug company cannot yet provide information about its cost-effectiveness.

Take PrepTest

Review Results

LSAT PrepTest 148 Explanations

Section 1 - Logical Reasoning

Section 2 - Reading Comprehension

Section 3 - Logical Reasoning

Section 4 - Logical Reasoning

Get full LSAT course

Leave a Reply